Regulatory approval

Published by the Health Canada. Approved

PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.

This is written in the approval document.

Citation

Hoffmann-La Roche Limited. Perjeta (pertuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060125.PDF. Published April 2013. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HC (1) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab
HC (1) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine

Contributions

Date Contributor Description
2024-10-30 Van Allen lab Initial access of FDA approvals